» Articles » PMID: 7504292

Expression and Functional Significance of an Additional Ligand for CTLA-4

Overview
Specialty Science
Date 1993 Dec 1
PMID 7504292
Citations 79
Authors
Affiliations
Soon will be listed here.
Abstract

Effective T-cell activation requires antigen/major histocompatibility complex engagement by the T-cell receptor complex in concert with one or more costimulatory molecules. Recent studies have suggested that the B7 molecule, expressed on most antigen presenting cells, functions as a costimulatory molecule through its interaction with CD28 on T cells. Blocking the CD28/B7 interaction with CTLA4Ig inhibits T-cell activation in vitro and induces unresponsiveness. We demonstrate that another molecule(s), termed B7-2, is expressed constitutively on dendritic cells, is differentially regulated on B cells, and costimulates naive T cells responding to alloantigen. B7-2 is up-regulated by lipopolysaccharide in < 6 hr and is maximally expressed on the majority of B cells by 24 hr. In contrast, B7 is detected only on a subset of activated B cells late (48 hr) after stimulation. In addition, Con A directly induces B7-2 but not B7 expression on B cells. Finally, although both anti-B7 monoclonal antibodies and CTLA4Ig blocked T-cell proliferation to antigen-expressing B7 transfectants, only CTLA4Ig had any significant inhibitory effect on T-cell proliferation to antigens expressed on natural antigen presenting cells, such as dendritic cells. Thus, B7 is not the only costimulatory molecule capable of initiating T-cell responses since a second ligand, B7-2, can provide a necessary second signal for T-cell activation.

Citing Articles

Neoadjuvant chemoradiotherapy up-regulates PD-L1 in radioresistant colorectal cancer.

Bae S, Lee H, Park J, Seo I, Cho J, Kim J Clin Transl Radiat Oncol. 2025; 51():100906.

PMID: 39811542 PMC: 11732604. DOI: 10.1016/j.ctro.2024.100906.


Utilising an in silico model to predict outcomes in senescence-driven acute liver injury.

Ashmore-Harris C, Antonopoulou E, Aird R, Man T, Finney S, Speel A NPJ Regen Med. 2024; 9(1):26.

PMID: 39349489 PMC: 11442582. DOI: 10.1038/s41536-024-00371-1.


A spatiotemporal map of co-receptor signaling networks underlying B cell activation.

Susa K, Bradshaw G, Eisert R, Schilling C, Kalocsay M, Blacklow S Cell Rep. 2024; 43(6):114332.

PMID: 38850533 PMC: 11256977. DOI: 10.1016/j.celrep.2024.114332.


Aging-related biomarker discovery in the era of immune checkpoint inhibitors for cancer patients.

Al-Danakh A, Safi M, Jian Y, Yang L, Zhu X, Chen Q Front Immunol. 2024; 15:1348189.

PMID: 38590525 PMC: 11000233. DOI: 10.3389/fimmu.2024.1348189.


Blocking Superantigen-Mediated Diseases: Challenges and Future Trends.

Wang P, Fredj Z, Zhang H, Rong G, Bian S, Sawan M J Immunol Res. 2024; 2024:2313062.

PMID: 38268531 PMC: 10807946. DOI: 10.1155/2024/2313062.


References
1.
Ranheim E, Kipps T . Activated T cells induce expression of B7/BB1 on normal or leukemic B cells through a CD40-dependent signal. J Exp Med. 1993; 177(4):925-35. PMC: 2190967. DOI: 10.1084/jem.177.4.925. View

2.
Linsley P, Greene J, Tan P, Bradshaw J, Ledbetter J, Anasetti C . Coexpression and functional cooperation of CTLA-4 and CD28 on activated T lymphocytes. J Exp Med. 1992; 176(6):1595-604. PMC: 2119471. DOI: 10.1084/jem.176.6.1595. View

3.
LINDSTEN T, Lee K, Harris E, Petryniak B, Craighead N, Reynolds P . Characterization of CTLA-4 structure and expression on human T cells. J Immunol. 1993; 151(7):3489-99. View

4.
Jenkins M, Taylor P, Norton S, Urdahl K . CD28 delivers a costimulatory signal involved in antigen-specific IL-2 production by human T cells. J Immunol. 1991; 147(8):2461-6. View

5.
Yamamura M, Uyemura K, Deans R, Weinberg K, Rea T, Bloom B . Defining protective responses to pathogens: cytokine profiles in leprosy lesions. Science. 1991; 254(5029):277-9. DOI: 10.1126/science.254.5029.277. View